This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

Summary

This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment duration (around 90 days). The study is looking at another research question: • What side effects may happen from taking the study drug

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Chronic Obstructive Pulmonary Disease (COPD)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 4

Ages

40 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Regeneron Pharmaceuticals

Last updated on ClinicalTrials.gov

October 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites